– In 2024, an estimated more than 12 patients received a life-saving transplant with the help of XVIVO's products and services, writes CEO Christoffer Rosenblad in the year-end report.
XVIVO Perfusion develops and sells systems for preserving organs outside the body for transplantation. The company offers a range of products in machine perfusion for lungs, heart, liver and kidney, as well as services for organ procurement and perfusion.
Sales for last year amounted to 822 million SEK, compared to just under 2023 million in 600. The company ended the year strong and beat analysts' expectations. Sales during the fourth quarter amounted to 228 million SEK, compared to Pinpoint's analyst consensus of 211 million. Behind the successes lies primarily the development in lung perfusion in the US and liver perfusion in Europe.
– All three business areas showed double-digit growth. All three areas have also increased their customer base during the year, notes rose leaf.
If he is to be believed, there is even more to come. The company continues to invest in the organization, with a particular focus on the commercial part “to meet the increasing demand for our products and services.”
Aiming for the heart
With a strong position in lung, liver and kidney, the next chapter for XVIVO will be to establish itself in the heart. The company is now awaiting regulatory approval from the European authorities, and intensive preparations for the launch are underway. As soon as the CE marking is in place, XVIVO will be ready to take its heart product to the market in Europe.
In the US, the last patient was enrolled in the company's clinical trial in the cardiac segment in November, reaching full enrollment five months earlier than planned. One-year data is expected by the end of 2025 and, following analysis, the regulatory process in the country will begin.
“The European study for our heart technology started in 2019 and now, almost six years later, we are just months away from launching in Europe. From the beginning, we had a strong belief that this technology would change the paradigm in heart transplantation,” emphasizes Christoffer Rosenblad.